Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rexall Sundown

This article was originally published in The Tan Sheet

Executive Summary

Expects fiscal first quarter sales to be 11%-12% higher than the prior-year period but below expectations due to a "slow down in retail sales within the nutritional industry," the Boca Raton, Fla.-based dietary supplement marketer announces Nov. 5. Rexall says market data indicate the industry growth rate is 15% for the latest four-week period, down 3.7% "sequentially during a period where the company expected a sequential increase. This slower than expected growth rate precipitated many retailers to realign their inventory positions and ordering patterns which adversely impacted sales in the first quarter" (ending Dec. 31). "We now believe industry has returned to its historical mid-teens growth more quickly than expected," the company says. For the last fiscal year, Rexall sales increased 82% to $531 mil

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS089062

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel